Clinicopathologic Prognostic Markers of Survival: an Analysis of 259 Patients with Malignant Melanoma >or=1 Mm

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2010 Mar 19

PMID 20237897

Authors

Friederike Egberts

A Momkvist

J H Egberts

K C Kaehler

M Weichenthal

A Hauschild

Affiliations

Soon will be listed here.

Abstract

The histopathologic status of the sentinel node (SN) and the ulceration of the primary tumor are important indicators of the clinical outcome of melanoma patients. The purpose of this study was to investigate potential correlations between prognostic factors and the sentinel lymph node status as well as their influence on disease-free survival (DFS), distant metastases-free survival (DMFS), and overall survival (OS). The medical records of 259 melanoma patients who underwent sentinel lymph node dissection between 2000 and 2006 were analyzed. DFS, DMFS, and OS were assessed. A uni- and a multivariate analysis to determine prognostic factors were performed. Histologic type, Clark's level, and Breslow's tumor thickness were the only parameters that showed a significant correlation with a positive SN. The univariate analysis revealed SN positivity (DFS and DMFS: p < 0.001; OS: p = 0.039) and ulceration (DFS: p < 0.001; DMFS: p = 0.001; OS: p = 0.003) to be significant prognostic markers. However, ulceration was the only independent prognostic factor for OS that was upheld by the multivariate analysis (p = 0.006; HR 3.89; CI 1.48-10.27). In stage I/II melanoma patients, ulceration of the primary tumor was the strongest prognostic factor for RFS, DMFS, and OS and superior to the pathology status of the SN.

References

Morton D, Cochran A, Thompson J . Authors' response to a letter to the editor re: Sentinel node biopsy for early-stage melanoma. Ann Surg. 2007; 245(5):828-9. PMC: 1877075. DOI: 10.1097/01.sla.0000261157.79250.16. View

Eigentler T, Caroli U, Radny P, Garbe C . Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 2003; 4(12):748-59. DOI: 10.1016/s1470-2045(03)01280-4. View

Thomas J . Time to re-evaluate sentinel node biopsy in melanoma post-multicenter selective lymphadenectomy trial. J Clin Oncol. 2005; 23(36):9443-4. DOI: 10.1200/JCO.2005.04.0147. View

Perrott R, Glass L, Reintgen D, Fenske N . Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol. 2003; 49(4):567-88. DOI: 10.1067/s0190-9622(03)02136-4. View

Roberts D, Anstey A, Barlow R, Cox N, Newton Bishop J, Corrie P . U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol. 2002; 146(1):7-17. DOI: 10.1046/j.1365-2133.2001.04614.x. View

Morton D, Thompson J, Cochran A, Mozzillo N, Elashoff R, Essner R . Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006; 355(13):1307-17. DOI: 10.1056/NEJMoa060992. View

Roka F, Kittler H, Cauzig P, Hoeller C, Hinterhuber G, Wolff K . Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer. 2005; 92(4):662-7. PMC: 2361872. DOI: 10.1038/sj.bjc.6602391. View

van Akkooi A, de Wilt J, Verhoef C, Graveland W, van Geel A, Kliffen M . High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer. 2006; 42(3):372-80. DOI: 10.1016/j.ejca.2005.10.023. View

Mohrle M, Breuninger H . [Sentinel node biopsy. What are the facts?]. Hautarzt. 2005; 56(5):441-7. DOI: 10.1007/s00105-005-0927-4. View

10.

Eggermont A, Suciu S, Santinami M, Testori A, Kruit W, Marsden J . Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008; 372(9633):117-126. DOI: 10.1016/S0140-6736(08)61033-8. View

11.

Zogakis T, Essner R, Wang H, Foshag L, Morton D . Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes. Ann Surg Oncol. 2007; 14(5):1604-11. DOI: 10.1245/s10434-006-9267-6. View

12.

van Akkooi A, de Wilt J, Verhoef C, Schmitz P, van Geel A, Eggermont A . Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?. Ann Oncol. 2006; 17(10):1578-85. DOI: 10.1093/annonc/mdl176. View

13.

Morton D, Wen D, Foshag L, Essner R, Cochran A . Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol. 1993; 11(9):1751-6. DOI: 10.1200/JCO.1993.11.9.1751. View

14.

Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V . Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma?. Cancer. 1999; 85(11):2391-9. DOI: 10.1002/(sici)1097-0142(19990601)85:11<2391::aid-cncr14>3.0.co;2-i. View

15.

Yee V, Thompson J, McKinnon J, Scolyer R, Li L, McCarthy W . Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol. 2005; 12(6):429-39. DOI: 10.1245/ASO.2005.03.074. View

16.

Twomey P . Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-1, an international multicenter trial. Ann Surg. 2007; 245(1):156-7. PMC: 1867950. DOI: 10.1097/01.sla.0000250942.84678.8b. View

17.

Medalie N, Ackerman A . Sentinel node biopsy has no benefit for patients whose primary cutaneous melanoma has metastasized to a lymph node and therefore should be abandoned now. Br J Dermatol. 2004; 151(2):298-307. DOI: 10.1111/j.1365-2133.2004.06132.x. View

18.

Kretschmer L, Hilgers R, Mohrle M, Balda B, Breuninger H, Konz B . Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer. 2004; 40(2):212-8. DOI: 10.1016/j.ejca.2003.07.003. View

19.

Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U . Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res. 2008; 18(1):61-7. DOI: 10.1097/CMR.0b013e3282f0c893. View

20.

Thomas J, Clark M . Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol. 2004; 30(6):686-91. DOI: 10.1016/j.ejso.2004.04.004. View